Coriolis Pharma appoints formulation expert Prof. Dr. Reza Nejadnik to its Scientific Advisory Board
Coriolis Pharma strengthens its presence in North America by appointing formulation expert Prof. Dr. Reza Nejadnik to its Scientific Advisory Board
Prof. Dr. Reza Nejadnik's research at the University of Iowa, College of Pharmacy, is focused on protein pharmaceuticals, their formulation and characterization, and interaction of biologics with interfaces.
Martinsried-Munich, Germany, February 1st, 2023 – Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines, appoints Prof. Dr. Reza Nejadnik to its scientific advisory board.
With this designation, Coriolis again strengthens its scientific expertise particularly in the area of protein formulation and analytics and provides clients in North America an additional point of contact for scientific questions.
Prof. Dr. Reza Nejadnik brings experience and expertise, both from academic and industrial work in the field of drug product development of biopharmaceuticals. Reza is currently a faculty member of the Department of Pharmaceutical Sciences and Experimental Therapeutics at the University of Iowa.
His research is focused on protein pharmaceuticals, their formulation and characterization, and interaction of biologics with interfaces. Delivery, handling and manufacturing processes of protein therapeutics are also among his topics of interest. Reza received his PhD from the University of Groningen in the Netherlands back in 2009. Following a few years of research in the area of proteins, nano and biomaterials at The University of Texas, Northwestern University and Radboud University Nijmegen, Reza joined the Leiden Academic Center for Drug Research in order to co-lead a European public-private partnership project (COMPACT) that addressed the current challenges with formulation and delivery of macromolecules. In the 4-year period of the COMPACT project, Reza’s research focused on characterization and understanding of protein aggregation in complex formulations as well as protein-material interactions. Reza then joined the Global Biologic Drug Product Development team of Sanofi and headed a formulation and process development laboratory in the Company’s R&D hub in Frankfurt, Germany. He developed early formulations and drug product manufacturing processes for several molecules in various modalities including antibodies and nanobodies.
“We warmly welcome Reza on board. With his extensive scientific expertise combined with industry experience in formulation and characterization of biopharmaceuticals he will be of great value for customer-specific questions in this area," said Silvia Steyrer-Gruber, Chief Executive Officer at Coriolis. "Reza is our third scientific advisor in North America, which will help us enormously to further expand our activities and presence in the US market.”
With Reza Nejadnik Coriolis expands its scientific advisory board to eleven members in total, including the most renowned specialists in biopharmaceutical formulation development and characterization. All of them are actively involved throughout client projects and contribute with advice to a successful outcome for the clients.
About Coriolis Pharma
Coriolis Pharma is a globally operating contract research organization and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. The company’s offering includes early and late-stage formulation development for liquid and lyophilized drug products, lyophilization process development and analytical development under R&D and GMP. Non-GMP manufacturing services for a wide range of products complete the service portfolio.
It is the vision of Coriolis to revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products. Coriolis Pharma thereby enables future therapies to be made available to humankind efficiently and on time.
With its interdisciplinary team of highly skilled scientists and an expert scientific advisory board, Coriolis provides cutting-edge services and tailor-made solutions for its clients. Founded in 2008 and headquartered in Martinsried near Munich, Germany, Coriolis currently employs more than 200 employees from over 35 nations around the world.